Selected research
Industry Research
Circulating Biomarker Industry Research Report 2026
Market perspective
The global Circulating Biomarker market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Circulating Biomarker is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Circulating Biomarker is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Circulating Biomarker is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Circulating Biomarker include GE Healthcare, Fluxion Biosciences, Epigenomics AG, Biocept, Becton, Dickinson and Company, Agilent Technologies, Affymetrix and Abbott Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Circulating Biomarker market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Circulating Biomarker Market by Company
GE Healthcare
Fluxion Biosciences
Epigenomics AG
Biocept
Becton, Dickinson and Company
Agilent Technologies
Affymetrix
Abbott Laboratories
Circulating Biomarker Segment by Type
Circulating DNA
Circulating Tumor Cells
Other
Circulating Biomarker Segment by Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring Orthopedics
Circulating Biomarker Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Biomarker market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Circulating Biomarker and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Biomarker.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Circulating Biomarker manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Circulating Biomarker by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Circulating Biomarker in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Circulating DNA
- Circulating Tumor Cells
- Other
Applications
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring Orthopedics
Companies covered
- GE Healthcare
- Fluxion Biosciences
- Epigenomics AG
- Biocept
- Becton, Dickinson and Company
- Agilent Technologies
- Affymetrix
- Abbott Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Circulating Biomarker Market Size (2021-2032)
- 2.2.2 Global Circulating Biomarker Sales (2021-2032)
- 2.2.3 Global Circulating Biomarker Market Average Price (2021-2032)
- 2.3 Circulating Biomarker by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Circulating DNA
- 2.3.3 Circulating Tumor Cells
- 2.3.4 Other
- 2.4 Circulating Biomarker by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Early Cancer Screening
- 2.4.3 Therapy Selection
- 2.4.4 Treatment Monitoring
- 2.4.5 Recurrence Monitoring Orthopedics
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Circulating Biomarker Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Circulating Biomarker Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Circulating Biomarker Revenue of Manufacturers (2021-2026)
- 3.4 Global Circulating Biomarker Average Price by Manufacturers (2021-2026)
- 3.5 Global Circulating Biomarker Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Circulating Biomarker, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Circulating Biomarker, Product Type & Application
- 3.8 Global Manufacturers of Circulating Biomarker, Established Date
- 3.9 Global Circulating Biomarker Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GE Healthcare
- 4.1.1 GE Healthcare Company Information
- 4.1.2 GE Healthcare Business Overview
- 4.1.3 GE Healthcare Circulating Biomarker Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GE Healthcare Circulating Biomarker Product Portfolio
- 4.1.5 GE Healthcare Recent Developments
- 4.2 Fluxion Biosciences
- 4.2.1 Fluxion Biosciences Company Information
- 4.2.2 Fluxion Biosciences Business Overview
- 4.2.3 Fluxion Biosciences Circulating Biomarker Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Fluxion Biosciences Circulating Biomarker Product Portfolio
- 4.2.5 Fluxion Biosciences Recent Developments
- 4.3 Epigenomics AG
- 4.3.1 Epigenomics AG Company Information
- 4.3.2 Epigenomics AG Business Overview
- 4.3.3 Epigenomics AG Circulating Biomarker Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Epigenomics AG Circulating Biomarker Product Portfolio
- 4.3.5 Epigenomics AG Recent Developments
- 4.4 Biocept
- 4.4.1 Biocept Company Information
- 4.4.2 Biocept Business Overview
- 4.4.3 Biocept Circulating Biomarker Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Biocept Circulating Biomarker Product Portfolio
- 4.4.5 Biocept Recent Developments
- 4.5 Becton, Dickinson and Company
- 4.5.1 Becton, Dickinson and Company Company Information
- 4.5.2 Becton, Dickinson and Company Business Overview
- 4.5.3 Becton, Dickinson and Company Circulating Biomarker Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Becton, Dickinson and Company Circulating Biomarker Product Portfolio
- 4.5.5 Becton, Dickinson and Company Recent Developments
- 4.6 Agilent Technologies
- 4.6.1 Agilent Technologies Company Information
- 4.6.2 Agilent Technologies Business Overview
- 4.6.3 Agilent Technologies Circulating Biomarker Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Agilent Technologies Circulating Biomarker Product Portfolio
- 4.6.5 Agilent Technologies Recent Developments
- 4.7 Affymetrix
- 4.7.1 Affymetrix Company Information
- 4.7.2 Affymetrix Business Overview
- 4.7.3 Affymetrix Circulating Biomarker Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Affymetrix Circulating Biomarker Product Portfolio
- 4.7.5 Affymetrix Recent Developments
- 4.8 Abbott Laboratories
- 4.8.1 Abbott Laboratories Company Information
- 4.8.2 Abbott Laboratories Business Overview
- 4.8.3 Abbott Laboratories Circulating Biomarker Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Abbott Laboratories Circulating Biomarker Product Portfolio
- 4.8.5 Abbott Laboratories Recent Developments
5 Global Circulating Biomarker Market Scenario by Region
- 5.1 Global Circulating Biomarker Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Circulating Biomarker Sales by Region: 2021-2032
- 5.2.1 Global Circulating Biomarker Sales by Region: 2021-2026
- 5.2.2 Global Circulating Biomarker Sales by Region: 2027-2032
- 5.3 Global Circulating Biomarker Revenue by Region: 2021-2032
- 5.3.1 Global Circulating Biomarker Revenue by Region: 2021-2026
- 5.3.2 Global Circulating Biomarker Revenue by Region: 2027-2032
- 5.4 North America Circulating Biomarker Market Facts & Figures by Country
- 5.4.1 North America Circulating Biomarker Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Circulating Biomarker Sales by Country (2021-2032)
- 5.4.3 North America Circulating Biomarker Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Circulating Biomarker Market Facts & Figures by Country
- 5.5.1 Europe Circulating Biomarker Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Circulating Biomarker Sales by Country (2021-2032)
- 5.5.3 Europe Circulating Biomarker Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Circulating Biomarker Market Facts & Figures by Country
- 5.6.1 Asia Pacific Circulating Biomarker Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Circulating Biomarker Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Circulating Biomarker Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Circulating Biomarker Market Facts & Figures by Country
- 5.7.1 South America Circulating Biomarker Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Circulating Biomarker Sales by Country (2021-2032)
- 5.7.3 South America Circulating Biomarker Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Circulating Biomarker Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Circulating Biomarker Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Circulating Biomarker Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Circulating Biomarker Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Circulating Biomarker Sales by Type (2021-2032)
- 6.1.1 Global Circulating Biomarker Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Circulating Biomarker Sales Market Share by Type (2021-2032)
- 6.2 Global Circulating Biomarker Revenue by Type (2021-2032)
- 6.2.1 Global Circulating Biomarker Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Circulating Biomarker Revenue Market Share by Type (2021-2032)
- 6.3 Global Circulating Biomarker Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Circulating Biomarker Sales by Application (2021-2032)
- 7.1.1 Global Circulating Biomarker Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Circulating Biomarker Sales Market Share by Application (2021-2032)
- 7.2 Global Circulating Biomarker Revenue by Application (2021-2032)
- 7.2.1 Global Circulating Biomarker Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Circulating Biomarker Revenue Market Share by Application (2021-2032)
- 7.3 Global Circulating Biomarker Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Circulating Biomarker Value Chain Analysis
- 8.1.1 Circulating Biomarker Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Circulating Biomarker Production Mode & Process
- 8.2 Circulating Biomarker Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Circulating Biomarker Distributors
- 8.2.3 Circulating Biomarker Customers
9 Global Circulating Biomarker Analyzing Market Dynamics
- 9.1 Circulating Biomarker Industry Trends
- 9.2 Circulating Biomarker Industry Drivers
- 9.3 Circulating Biomarker Industry Opportunities and Challenges
- 9.4 Circulating Biomarker Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst